P053 Real-life experience with a generic formulation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis with responsive CFTR variants without previous modulators therapy.

Autor: Teper, A.1 (AUTHOR), Lubovich, S.1 (AUTHOR), Zaragoza, S.1 (AUTHOR), Rodriguez, V.1 (AUTHOR), Rodriguez, E.1 (AUTHOR), Bracamonte, F.1 (AUTHOR), Ray, L.1 (AUTHOR), Frias, G.1 (AUTHOR), Garcia Bournissen, F.2 (AUTHOR)
Zdroj: Journal of Cystic Fibrosis. 2024 Supplement 1, Vol. 23, pS82-S83. 2p.
Databáze: Academic Search Ultimate
Externí odkaz: